Silence Therapeutics plc
SLN
$7.35
$0.456.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.87% | -89.39% | -70.37% | -99.10% | 1,168.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.87% | -89.39% | -70.37% | -99.10% | 1,168.36% |
| Cost of Revenue | -99.41% | -98.24% | -97.45% | -98.07% | 41.64% |
| Gross Profit | -99.91% | 104.44% | 105.39% | -99.32% | 4,083.21% |
| SG&A Expenses | -32.62% | -24.71% | -26.79% | 15.81% | 7.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.59% | -11.81% | -4.30% | 37.73% | 213.16% |
| Operating Income | -3,750.91% | 7.25% | 1.88% | -733.77% | 94.70% |
| Income Before Tax | -193.22% | 40.96% | -40.03% | -1,279.59% | 253.00% |
| Income Tax Expenses | -100.00% | -97.96% | -95.61% | -- | -96.49% |
| Earnings from Continuing Operations | -195.68% | 41.04% | -38.47% | -1,134.00% | 170.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -195.68% | 41.04% | -38.47% | -1,134.00% | 170.40% |
| EBIT | -3,750.91% | 7.25% | 1.88% | -733.77% | 94.70% |
| EBITDA | -6,558.51% | 7.31% | 1.88% | -772.26% | 96.89% |
| EPS Basic | -195.66% | 41.25% | -37.00% | -1,048.48% | 158.02% |
| Normalized Basic EPS | -193.18% | 41.16% | -31.87% | -1,184.35% | 226.11% |
| EPS Diluted | -195.66% | 41.25% | -37.00% | -1,048.48% | 158.02% |
| Normalized Diluted EPS | -193.18% | 41.16% | -31.87% | -1,184.35% | 226.11% |
| Average Basic Shares Outstanding | 0.01% | 0.36% | 1.06% | 7.43% | 21.34% |
| Average Diluted Shares Outstanding | 0.01% | 0.36% | 1.06% | 7.43% | 21.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |